Published in Eur Respir J on May 01, 2005
Pathology of pulmonary hypertension. Clin Chest Med (2007) 2.34
Circulating collagen biomarkers as indicators of disease severity in pulmonary arterial hypertension. JACC Heart Fail (2014) 1.52
Role of the TGF-beta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension. Am J Respir Crit Care Med (2008) 1.37
Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm (2013) 1.25
Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells. Respir Res (2006) 1.00
Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. Respir Res (2011) 0.92
Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotaline-treated rats. Acta Pharmacol Sin (2011) 0.92
Gene expressions of nitric oxide synthase and matrix metalloproteinase-2 in monocrotaline-induced pulmonary hypertension in rats after bosentan treatment. Korean Circ J (2011) 0.91
CPU86017 and its isomers improve hypoxic pulmonary hypertension by attenuating increased ETA receptor expression and extracellular matrix accumulation. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.89
Cell-specific dual role of caveolin-1 in pulmonary hypertension. Pulm Med (2011) 0.87
Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMα) in chronic hypoxia- and antigen-mediated pulmonary vascular remodeling. Respir Res (2013) 0.87
Deciphering the "matrix" in pulmonary vascular remodelling. Eur Respir J (2005) 0.87
Upregulated genes in sporadic, idiopathic pulmonary arterial hypertension. Respir Res (2006) 0.87
PPARgamma as a potential therapeutic target in pulmonary hypertension. Ther Adv Respir Dis (2010) 0.87
Hypoxia-induced mitogenic factor (FIZZ1/RELMα) induces endothelial cell apoptosis and subsequent interleukin-4-dependent pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2014) 0.87
NOX4 mediates activation of FoxO3a and matrix metalloproteinase-2 expression by urotensin-II. Mol Biol Cell (2011) 0.86
Inhaled PLGA particles of prostaglandin E₁ ameliorate symptoms and progression of pulmonary hypertension at a reduced dosing frequency. Mol Pharm (2013) 0.85
Human herpesvirus-8 infection of primary pulmonary microvascular endothelial cells. Am J Respir Cell Mol Biol (2008) 0.83
Gene expression analysis of a murine model with pulmonary vascular remodeling compared to end-stage IPAH lungs. Respir Res (2012) 0.82
Transgenic expression of human matrix metalloproteinase-9 augments monocrotaline-induced pulmonary arterial hypertension in mice. J Hypertens (2011) 0.82
Pleiotropic effects of statins in distal human pulmonary artery smooth muscle cells. Respir Res (2011) 0.81
Vitamin D induces increased systolic arterial pressure via vascular reactivity and mechanical properties. PLoS One (2014) 0.81
Novel mechanisms of sildenafil in pulmonary hypertension involving cytokines/chemokines, MAP kinases and Akt. PLoS One (2014) 0.81
Compartment-specific expression of collagens and their processing enzymes in intrapulmonary arteries of IPAH patients. Am J Physiol Lung Cell Mol Physiol (2015) 0.79
A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents. Am J Respir Crit Care Med (2012) 0.79
Microvessel mechanobiology in pulmonary arterial hypertension: cause and effect. Hypertension (2014) 0.78
Pulmonary hypertension and vascular remodeling in mice exposed to crystalline silica. Respir Res (2016) 0.78
Inflammatory response mechanisms exacerbating hypoxemia in coexistent pulmonary fibrosis and sleep apnea. Mediators Inflamm (2015) 0.77
Hypoxia-Inducible Factor 1α Is a Critical Downstream Mediator for Hypoxia-Induced Mitogenic Factor (FIZZ1/RELMα)-Induced Pulmonary Hypertension. Arterioscler Thromb Vasc Biol (2015) 0.77
A translational preclinical model of interstitial pulmonary fibrosis and pulmonary hypertension: mechanistic pathways driving disease pathophysiology. Physiol Rep (2014) 0.77
Retracted Transgenic expression of human matrix metalloproteinase-1 attenuates pulmonary arterial hypertension in mice. Clin Sci (Lond) (2012) 0.77
Pulmonary hypertension caused by pulmonary venous hypertension. Pulm Circ (2014) 0.76
Baicalin Attenuates Hypoxia-Induced Pulmonary Arterial Hypertension to Improve Hypoxic Cor Pulmonale by Reducing the Activity of the p38 MAPK Signaling Pathway and MMP-9. Evid Based Complement Alternat Med (2016) 0.75
Activation of AMPK Prevents Monocrotaline-Induced Extracellular Matrix Remodeling of Pulmonary Artery. Med Sci Monit Basic Res (2016) 0.75
Evaluation of circulating proteins and hemodynamics towards predicting mortality in children with pulmonary arterial hypertension. PLoS One (2013) 0.75
Investigation of MMP-2 and MMP-9 activities in canine sera with dilated cardiomyopathy. Iran J Vet Res (2015) 0.75
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 12.35
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med (2001) 6.73
Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J (2009) 6.64
Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med (2001) 3.29
Inflammation in pulmonary arterial hypertension. Eur Respir J (2003) 3.18
Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet (2000) 2.82
Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest (2001) 2.59
BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet (2000) 2.51
Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J (2009) 2.41
Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats. Eur Respir J (2004) 2.40
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis (2006) 2.28
Surgical management of mediastinal goiters: when is a sternotomy required? Thorac Cardiovasc Surg (2007) 2.28
Development of an acellular pertussis vaccine and its administration as a booster in healthy adults. Vaccine (1991) 2.21
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J (1998) 2.14
Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax (2005) 2.03
Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. Am J Respir Cell Mol Biol (1996) 1.96
High expression of 92-kD type IV collagenase (gelatinase B) in the osteoclast lineage during mouse development. J Cell Biol (1994) 1.96
Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J Clin Invest (1991) 1.91
Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med (2007) 1.86
Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J (2009) 1.85
Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation (2005) 1.84
Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest (2000) 1.80
Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J (2006) 1.78
MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J (2002) 1.77
[Guidelines for the diagnosis and treatment of pulmonary hypertension]. Rev Mal Respir (2010) 1.74
Chronic thromboembolic pulmonary hypertension. Eur Respir J (2004) 1.74
Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med (2002) 1.65
Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy (2004) 1.61
Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol (1997) 1.59
Expression of matrix metalloproteinases 2 and 9 in regenerating skeletal muscle: a study in experimentally injured and mdx muscles. Dev Biol (1999) 1.58
Association of pulmonary aspergilloma and allergic bronchopulmonary aspergillosis. Eur Respir Rev (2010) 1.51
Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood (2001) 1.51
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J (2007) 1.51
Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie (2007) 1.49
Immunomodulation with low-dose immunoglobulins for moderate IgA nephropathy and Henoch-Schönlein purpura. Preliminary results of a prospective uncontrolled trial. Nephron (1995) 1.45
Surgical treatment of pulmonary aspergilloma: current outcome. J Thorac Cardiovasc Surg (2000) 1.45
Pulmonary vascular disorders in portal hypertension. Eur Respir J (1998) 1.44
5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol (2000) 1.42
Longitudinal study of asymptomatic meningococcal carriage in two Belgian populations of schoolchildren. J Infect (1983) 1.42
Prioritised research agenda for prevention and control of chronic respiratory diseases. Eur Respir J (2010) 1.41
[Adult asthma exacerbations in questions]. Rev Mal Respir (2010) 1.40
Evidence of endogenous volatile organic compounds as biomarkers of diseases in alveolar breath. Ann Pharm Fr (2013) 1.40
Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax (2004) 1.40
Case 4-1993. Inhaled nitric oxide for right ventricular failure after heart transplantation. J Cardiothorac Vasc Anesth (1993) 1.39
Fatal rupture of pulmonary arteriovenous malformation in hereditary haemorrhagic telangiectasis and severe PAH. Eur Respir Rev (2009) 1.39
Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relationship with the mitogenic action of serotonin. Circ Res (1999) 1.37
Pulmonary veno-occlusive disease. Eur Respir J (2009) 1.37
MMP-2- and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol (2000) 1.33
Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J Neurol Sci (1997) 1.32
Long term imatinib treatment in pulmonary arterial hypertension. Thorax (2006) 1.32
Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett (1997) 1.30
Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax (2005) 1.29
Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J (2001) 1.29
Vascular endothelial growth factor synthesis in the acute phase of experimental and clinical lung injury. Eur Respir J (2001) 1.26
Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper. Allergy (2010) 1.24
Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med (2000) 1.23
Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest (1998) 1.22
Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis (2007) 1.21
Guidelines on the standards for the training of specialised health professionals dealing with breast cancer. Eur J Cancer (2007) 1.20
Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. Allergy (2008) 1.20
Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst (1994) 1.20
Evaluation and outcome of different surgical techniques for postintubation tracheoesophageal fistulas. J Thorac Cardiovasc Surg (2000) 1.19
Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia--a step forward but not the definitive answer. J Reprod Immunol (2009) 1.19
Clamshell or sternotomy for double lung or heart-lung transplantation? Eur J Cardiothorac Surg (1999) 1.19
Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway. Mol Cell Biol (2001) 1.19
Overexpression of alveolar macrophage gelatinase B (MMP-9) in patients with idiopathic pulmonary fibrosis: effects of steroid and immunosuppressive treatment. Am J Respir Cell Mol Biol (1999) 1.19
Decreased VEGF concentration in lung tissue and vascular injury during ARDS. Eur Respir J (2005) 1.17
Membrane type-matrix metalloproteinases and tumor progression. Biochimie (2005) 1.16
Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur Respir J (2001) 1.15
Basophils, eosinophils, and mast cells in atopic and nonatopic asthma and in late-phase allergic reactions in the lung and skin. J Allergy Clin Immunol (2000) 1.15
Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. Matrix Biol (2003) 1.15
Treatment with 5-HT potentiates development of pulmonary hypertension in chronically hypoxic rats. Am J Physiol (1997) 1.14
Angiotensin II induces nuclear factor- kappa B activation in cultured neonatal rat cardiomyocytes through protein kinase C signaling pathway. J Mol Cell Cardiol (2000) 1.14
Expression and regulation of vascular endothelial growth factor in human pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol (2000) 1.13
Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension. Eur Respir J (2010) 1.13
Mouse B lymphocyte specific endocytosis and recycling of MHC class II molecules. EMBO J (1990) 1.12
Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats. Am J Respir Cell Mol Biol (2000) 1.12
Contribution of MT1-MMP and of human laminin-5 gamma2 chain degradation to mammary epithelial cell migration. J Cell Sci (2001) 1.12
Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. Eur Respir J (2006) 1.11
Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J (2006) 1.11
Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC). Br J Cancer (2006) 1.11
Neonatal diagnosis of HIV infection. Lancet (1991) 1.11
Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med (2001) 1.11